Well Referenced

Tag: EHS

Penile low intensity shock wave treatment for PDE5I refractory erectile dysfunction: a randomized double-blind sham-controlled clinical trial

This randomized, double-blind, sham-controlled clinical trial assessed the efficacy of low-intensity extracorporeal shockwave therapy (LI-ESWT) in 76 men with vascular erectile dysfunction (ED) unresponsive to phosphodiesterase type 5 inhibitors (PDE5Is). Participants received weekly sessions for four weeks (5000 shocks/session at 0.09 mJ/mm²). At 3 months, the treatment group showed a

Read More »
June 26, 2025 No Comments

Are Radial Pressure Waves Effective for the Treatment of Moderate or Mild to Moderate Erectile Dysfunction? A Randomized Sham Therapy Controlled Clinical Trial

This 2022 randomized, double-blind, sham-controlled clinical trial assessed the efficacy and safety of radial pressure wave therapy (RPWT) in 80 men with moderate or mild to moderate erectile dysfunction (ED). Participants received six weekly sessions of RPWT or sham therapy, alongside daily sildenafil (25 mg). At six weeks, the mean

Read More »
June 26, 2025 No Comments

Low Intensity Shockwave Therapy in Combination with Phosphodiesterase-5 Inhibitors is an Effective and Safe Treatment Option in Patients with Vasculogenic ED who are PDE5i Non-responders: A Multicenter Single-arm Clinical Trial

This 2021 multicenter, open-label prospective study evaluated the safety and efficacy of combining low-intensity extracorporeal shockwave therapy (Li-ESWT) with phosphodiesterase-5 inhibitors (PDE5i) in 109 men with vasculogenic erectile dysfunction (ED) unresponsive to PDE5i monotherapy. Li-ESWT was administered twice weekly for 3 weeks, delivering 3,000 shockwaves per session at 0.25 mJ/mm²

Read More »
June 26, 2025 No Comments

Safety and Efficacy of 2 Intracavernous Injections of Allogeneic Wharton’s Jelly-Derived Mesenchymal Stem Cells in Diabetic Patients with Erectile Dysfunction: Phase 1/2 Clinical Trial

This 2021 phase 1/2 clinical trial evaluated the safety and efficacy of two intracavernous injections of allogeneic Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) in 22 diabetic men with refractory erectile dysfunction (ED). The procedure was well-tolerated, with only minimal and transient adverse events such as redness and bruising at the

Read More »
June 26, 2025 No Comments